Transparency Market Research has published a new report on the global immunoprotein diagnostic testing market. According to the report, the global immunoprotein diagnostic testing market stood at US$11.02 bn in 2012 and is expected to reach US$15.35 bn by 2019, progressing at a 5.70% CAGR from 2013 to 2019. The report, titled 'Immunoprotein Diagnostic Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,' states that the global immunoprotein diagnostic testing market is expected to expand rapidly due to the commoditization of products, the rising need for quick diagnosis of diseases, and the increasing demand for preventive healthcare in developing nations.
Get Free Sample Research Report:
Immunoproteins are a part of the body's defense mechanism and show characteristic serum concentration under certain abnormal conditions. The concentration of immunoproteins has been a major indicator for the diagnosis of a diseased state. When exposed to an antigen, the level of immunoproteins increases 10- to 100-fold within 24 to 48 hours. The applications of immunoproteins have shifted from microbial testing to rapid testing.
Technological advancements and a strong network of distributors are two of the important factors expected to drive the global immunoprotein diagnostic testing market in the years to come. The higher cost of immunoprotein-based diagnosis and the existing installed base of traditional ELISA are predicted to restrict the growth of the global immunoprotein diagnostic testing market. However, improved research and development activities, expansion of the technique in emerging economies, and the uptake of immunochromatography are predicted to create growth opportunities in the global immunoprotein diagnostic testing market in the near future.
The global immunoprotein diagnostic testing market is segmented on the basis of immunoprotein type, geography, application, and assay technology. Based on type, the global immunoprotein diagnostic testing market is classified into free light chain diagnostic tests, C-reactive protein diagnostic tests, immunoglobulin diagnostic tests, complement system protein diagnostic tests, and haptoglobin diagnostic tests. Currently, the global immunoprotein diagnostic testing market is dominated by the C-reactive protein diagnostic test segment due to its accurate and effective diagnosis of inflammation-related disorders, injuries, cardiovascular diseases, and strokes.
By technology, the global immunoprotein diagnostic testing market is classified into enzyme-based immunoassay, chemiluminescence assay, immunoprotein electrophoresis, immunoturbidity, and radioimmunoassay. The global immunoprotein diagnostic testing market, in 2012, was dominated by the chemiluminescence assay segment due to its ease of use, safety, and feasibility in various conditions. Some of the applications of immunoprotein diagnostic testing are in toxicology testing, autoimmune disease testing, endocrine testing, infectious diseases, allergy testing, and oncology testing. The oncology testing segment is predicted to reach US$4.94 bn by 2019, and is expected to expand at a 6.0% CAGR from 2013 to 2019.
Based on geography, the global immunoprotein diagnostic testing market is divided into Europe, Asia Pacific, North America, and the Rest of the World. DiaSorin SPA, The Binding Site Group Ltd., Omega Diagnostics Group PLC, Siemens AG, Roche Holding AG, Abbott Laboratories, Inc., Thermo Fisher Scientific, Inc., Abcam PLC, Randox Laboratories Ltd., Enzo Life Sciences, Inc., and Fujirebio Diagnostics, Inc. are some of the prominent companies in the global immunoprotein diagnostic testing market.
Full Research Report on Global Immunoprotein Diagnostic Testing Market: